PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.
Related news for (PXMD)
- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
- Threshold List Stocks with Upcoming Catalysts
- PaxMedica Meets Key PAX-101 Development Milestone and May Submit NDA